Clinical trial
Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
NCT06010212 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- August 25, 2023
- Completion date
- July 1, 2026
- Enrollment
- 36 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.